patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_493816 | REC_0001301 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.5 | 66 | female | 1 | 15 | 5.2 | 3 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:35:57.163705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176667 | REC_0001302 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.1 | 67 | female | 0 | 8 | 4.8 | 1 | entrectinib 600 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:57.163947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932207 | REC_0001303 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 8.3 | 78 | male | 1 | 31 | 5.9 | 5 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:35:57.164228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552828 | REC_0001304 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.7 | 54 | female | 0 | 16 | 5.5 | 4 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:57.164477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393976 | REC_0001305 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.8 | 72 | female | 1 | 23 | 8.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.7 | false | MSS | 2026-03-15T05:35:57.164709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748647 | REC_0001306 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.7 | 60 | male | 0 | 18 | 3.9 | 1 | osimertinib 80 mg daily | 25 | false | MSI-H | 2026-03-15T05:35:57.164960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197219 | REC_0001307 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 5.4 | 72 | female | 2 | 15 | 4.5 | 5 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:57.165203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506162 | REC_0001308 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 5.3 | 68 | male | 1 | 11 | 5.2 | 2 | alectinib 600 mg BID | 14.3 | false | MSS | 2026-03-15T05:35:57.165449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390663 | REC_0001309 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 18.6 | 66 | female | 0 | 17 | 6.1 | 7 | sotorasib 960 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:35:57.165698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217331 | REC_0001310 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 15.9 | 67 | female | 0 | 25 | 4.3 | 1 | osimertinib 80 mg daily | 18.7 | true | MSI-H | 2026-03-15T05:35:57.165952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460935 | REC_0001311 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 13.9 | 74 | female | 1 | 21 | 5.6 | 1 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:57.166228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438903 | REC_0001312 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 7.6 | 87 | female | 3 | 19 | 5.7 | 6 | alectinib 600 mg BID | 11.5 | true | MSS | 2026-03-15T05:35:57.166503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464473 | REC_0001313 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.5 | 78 | female | 0 | 27 | 3.8 | 7 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:57.166774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935210 | REC_0001314 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.8 | 65 | male | 0 | 17 | 7.3 | 6 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:57.167215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245541 | REC_0001315 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.5 | 73 | female | 1 | 19 | 4.4 | 5 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.167542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111531 | REC_0001316 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 17 | 66 | male | 1 | 3 | 6.6 | 1 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.167880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269058 | REC_0001317 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 5.2 | 63 | female | 1 | 9 | 6.1 | 0 | entrectinib 600 mg daily | 46.2 | false | MSS | 2026-03-15T05:35:57.168230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859066 | REC_0001318 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 9.3 | 65 | female | 1 | 9 | 5.4 | 6 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:57.168530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757007 | REC_0001319 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7.5 | 66 | female | 0 | 13 | 6 | 6 | entrectinib 600 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:57.168796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_531220 | REC_0001320 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.7 | 60 | male | 0 | 23 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:35:57.169039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865106 | REC_0001321 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 8.5 | 59 | female | 0 | 12 | 5 | 8 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.169279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983415 | REC_0001322 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 15.5 | 72 | female | 3 | 11 | 5.5 | 2 | alectinib 600 mg BID | 16.8 | false | MSS | 2026-03-15T05:35:57.169523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645542 | REC_0001323 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.7 | 67 | female | 0 | 13 | 3.8 | 1 | osimertinib 80 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:57.169763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577207 | REC_0001324 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.3 | 59 | female | 0 | 9 | 6.7 | 4 | alectinib 600 mg BID | 14.5 | true | MSS | 2026-03-15T05:35:57.170007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308608 | REC_0001325 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.6 | 61 | female | 1 | 7 | 7.4 | 5 | entrectinib 600 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:57.170246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645354 | REC_0001326 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.2 | 55 | male | 0 | 37 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.7 | false | MSS | 2026-03-15T05:35:57.170480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734969 | REC_0001327 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 18.1 | 74 | female | 1 | 2 | 5.3 | 1 | alectinib 600 mg BID | 20.6 | true | MSS | 2026-03-15T05:35:57.170823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589096 | REC_0001328 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12.6 | 68 | female | 1 | 19 | 5.8 | 2 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.171070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173452 | REC_0001329 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.9 | 74 | male | 2 | 0 | 6.8 | 2 | osimertinib 80 mg daily | 16.8 | true | MSI-H | 2026-03-15T05:35:57.171307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269990 | REC_0001330 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 15.8 | 60 | female | 1 | 23 | 5.9 | 1 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:57.171545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863909 | REC_0001331 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 10.1 | 62 | male | 0 | 5 | 5 | 6 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.171782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757679 | REC_0001332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.2 | 54 | male | 0 | 23 | 7.5 | 6 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.172015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662521 | REC_0001333 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 15.7 | 64 | male | 0 | 7 | 5.4 | 2 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.172320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146369 | REC_0001334 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 10.1 | 75 | male | 2 | 70 | 4.4 | 7 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:35:57.172563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925464 | REC_0001335 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 10.2 | 74 | male | 2 | 20 | 5.6 | 1 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.172808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338512 | REC_0001336 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 16.4 | 67 | female | 1 | 11 | 3.6 | 8 | osimertinib 80 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:57.173041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415257 | REC_0001337 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.8 | 74 | female | 1 | 58 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:57.173273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475798 | REC_0001338 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.7 | 61 | female | 0 | 6 | 5.7 | 6 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:57.173509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707552 | REC_0001339 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 18.8 | 65 | female | 1 | 19 | 5.8 | 2 | osimertinib 80 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:57.173746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146263 | REC_0001340 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 10.5 | 85 | male | 0 | 29 | 8.2 | 6 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:35:57.174041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621101 | REC_0001341 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.5 | 72 | female | 1 | 15 | 5.9 | 7 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:35:57.174273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747307 | REC_0001342 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.5 | 83 | female | 2 | 8 | 6.2 | 8 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:57.174505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317362 | REC_0001343 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 10.9 | 67 | female | 0 | 14 | 6 | 5 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.174740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950402 | REC_0001344 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 17.1 | 66 | female | 1 | 17 | 8.1 | 1 | osimertinib 80 mg daily | 20 | false | MSI-H | 2026-03-15T05:35:57.174971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888852 | REC_0001345 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.7 | 62 | female | 1 | 58 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.2 | true | MSS | 2026-03-15T05:35:57.175202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543471 | REC_0001346 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 7.6 | 86 | female | 2 | 13 | 5 | 5 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:57.175430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363729 | REC_0001347 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 5 | 62 | male | 0 | 7 | 3.6 | 2 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:57.175661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351361 | REC_0001348 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.2 | 49 | female | 0 | 15 | 2.9 | 7 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:57.175893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571048 | REC_0001349 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.6 | 70 | male | 2 | 4 | 7.8 | 7 | osimertinib 80 mg daily | 20 | true | MSI-H | 2026-03-15T05:35:57.176247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131391 | REC_0001350 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 17.6 | 55 | male | 1 | 22 | 4.7 | 2 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:57.176493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933295 | REC_0001351 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.4 | 61 | female | 0 | 5 | 7 | 5 | alectinib 600 mg BID | 7.4 | true | MSS | 2026-03-15T05:35:57.176734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435609 | REC_0001352 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.9 | 75 | male | 3 | 16 | 5.2 | 6 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:57.176970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933587 | REC_0001353 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10.6 | 64 | male | 1 | 8 | 5.3 | 8 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:57.177261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529378 | REC_0001354 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 9.8 | 71 | female | 2 | 19 | 6.6 | 1 | osimertinib 80 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:57.177493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880625 | REC_0001355 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 11.5 | 62 | female | 1 | 4 | 5.5 | 2 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:35:57.177729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398198 | REC_0001356 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 5.8 | 68 | female | 1 | 10 | 4.2 | 6 | alectinib 600 mg BID | 6.4 | true | MSS | 2026-03-15T05:35:57.177958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871848 | REC_0001357 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14 | 70 | male | 1 | 11 | 4.8 | 7 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:57.178193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365027 | REC_0001358 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11.2 | 56 | female | 0 | 18 | 6.7 | 1 | sotorasib 960 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:35:57.178428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403979 | REC_0001359 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.4 | 59 | female | 0 | 52 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.1 | true | MSS | 2026-03-15T05:35:57.178664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668288 | REC_0001360 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.4 | 87 | female | 2 | 20 | 6 | 6 | sotorasib 960 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:57.178916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230316 | REC_0001361 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 11.2 | 71 | female | 0 | 27 | 6.4 | 5 | sotorasib 960 mg daily | 6.9 | true | MSS | 2026-03-15T05:35:57.179181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349365 | REC_0001362 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 16.1 | 72 | female | 2 | 8 | 4.7 | 6 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.179434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559462 | REC_0001363 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.2 | 66 | female | 0 | 8 | 4.7 | 5 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:57.179675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179034 | REC_0001364 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 17.9 | 72 | female | 2 | 21 | 4.1 | 1 | entrectinib 600 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:35:57.179924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427406 | REC_0001365 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.9 | 70 | female | 1 | 16 | 6.3 | 5 | osimertinib 80 mg daily | 6.1 | true | MSI-H | 2026-03-15T05:35:57.180207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256472 | REC_0001366 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 11.4 | 68 | female | 1 | 1 | 8.5 | 2 | osimertinib 80 mg daily | 24.9 | false | MSI-H | 2026-03-15T05:35:57.180543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552648 | REC_0001367 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 6.2 | 64 | male | 0 | 15 | 4.2 | 7 | osimertinib 80 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:57.180790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560431 | REC_0001368 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.6 | 66 | female | 1 | 15 | 6.4 | 7 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.181021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249080 | REC_0001369 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 12.6 | 67 | female | 1 | 11 | 6 | 1 | osimertinib 80 mg daily | 17.3 | false | MSI-H | 2026-03-15T05:35:57.181256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206120 | REC_0001370 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.9 | 65 | male | 0 | 13 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:35:57.181499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189465 | REC_0001371 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.7 | 61 | female | 0 | 11 | 4.5 | 3 | entrectinib 600 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.181759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836242 | REC_0001372 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.4 | 63 | male | 1 | 15 | 7.8 | 1 | alectinib 600 mg BID | 23.8 | false | MSI-H | 2026-03-15T05:35:57.182023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846809 | REC_0001373 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.2 | 54 | female | 0 | 1 | 3.3 | 1 | alectinib 600 mg BID | 18.5 | true | MSS | 2026-03-15T05:35:57.182273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612335 | REC_0001374 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.4 | 68 | female | 1 | 14 | 5.1 | 5 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:57.182507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385382 | REC_0001375 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10.8 | 53 | female | 0 | 11 | 7.4 | 3 | entrectinib 600 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:57.182743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621959 | REC_0001376 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.9 | 61 | female | 0 | 2 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:35:57.182976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856098 | REC_0001377 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8 | 61 | female | 1 | 28 | 7.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.6 | false | MSS | 2026-03-15T05:35:57.183209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158523 | REC_0001378 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 15 | 67 | female | 1 | 16 | 5.9 | 6 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:35:57.183441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670322 | REC_0001379 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 2.1 | 71 | female | 2 | 12 | 3.1 | 6 | entrectinib 600 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:57.183772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214877 | REC_0001380 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.1 | 65 | female | 0 | 12 | 3.5 | 5 | alectinib 600 mg BID | 16.8 | true | MSI-H | 2026-03-15T05:35:57.184029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894984 | REC_0001381 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 9.3 | 64 | male | 0 | 9 | 5.9 | 7 | entrectinib 600 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.184421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539108 | REC_0001382 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 20.1 | 66 | female | 1 | 14 | 5 | 7 | sotorasib 960 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:35:57.184680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432087 | REC_0001383 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.2 | 69 | female | 1 | 15 | 2.9 | 1 | alectinib 600 mg BID | 9.7 | true | MSI-H | 2026-03-15T05:35:57.184924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816189 | REC_0001384 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 7.7 | 75 | female | 1 | 13 | 4.5 | 7 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.185177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879887 | REC_0001385 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.5 | 69 | female | 1 | 67 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.2 | true | MSS | 2026-03-15T05:35:57.185414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119532 | REC_0001386 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.5 | 68 | male | 1 | 17 | 6.1 | 7 | sotorasib 960 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:57.185658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907926 | REC_0001387 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.1 | 73 | male | 2 | 22 | 3 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.8 | false | MSS | 2026-03-15T05:35:57.185897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650286 | REC_0001388 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.8 | 84 | female | 2 | 11 | 6.7 | 6 | alectinib 600 mg BID | 10.8 | false | MSI-H | 2026-03-15T05:35:57.186142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499917 | REC_0001389 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.7 | 77 | male | 2 | 14 | 6.5 | 4 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.186383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511730 | REC_0001390 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 13.4 | 63 | female | 0 | 15 | 6.6 | 3 | osimertinib 80 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:57.186623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513899 | REC_0001391 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.2 | 81 | female | 0 | 7 | 4.3 | 5 | alectinib 600 mg BID | 14 | true | MSS | 2026-03-15T05:35:57.186863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901116 | REC_0001392 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 3.7 | 88 | female | 2 | 28 | 6.1 | 1 | sotorasib 960 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:57.187199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324133 | REC_0001393 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.3 | 58 | male | 1 | 24 | 5.3 | 4 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:57.187446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108374 | REC_0001394 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.4 | 71 | female | 2 | 14 | 5 | 2 | osimertinib 80 mg daily | 5.8 | false | MSI-H | 2026-03-15T05:35:57.187679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881889 | REC_0001395 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.4 | 64 | male | 0 | 16 | 5.2 | 5 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:57.187911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411428 | REC_0001396 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 12.4 | 53 | female | 0 | 17 | 5.1 | 2 | alectinib 600 mg BID | 16.3 | false | MSI-H | 2026-03-15T05:35:57.188208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491814 | REC_0001397 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 21 | 73 | male | 2 | 13 | 5.1 | 4 | alectinib 600 mg BID | 11.7 | false | MSI-H | 2026-03-15T05:35:57.188464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912254 | REC_0001398 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 13.5 | 64 | female | 1 | 9 | 7.1 | 2 | entrectinib 600 mg daily | 21.3 | false | MSI-H | 2026-03-15T05:35:57.188702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957364 | REC_0001399 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 13.2 | 67 | female | 1 | 21 | 6.7 | 0 | sotorasib 960 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:57.188939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272400 | REC_0001400 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.8 | 60 | female | 1 | 34 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:57.189173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.